



*Press Release*

*For Immediate Release*

July 1, 2007

## M's Science Corporation Appoints Roman Urfer as Senior Vice President of International Development

---

Kobe, Japan: July 1, 2007 - M's Science Corporation, a clinical stage discovery and development company announced today that it has named Roman Urfer, Ph.D., as Senior Vice President of International Development. In this position, Dr. Urfer will be responsible for managing the clinical development of our most advanced products SA4503 and HF10. In addition, Dr. Urfer will identify and pursue international business development opportunities for our main products.

Before joining M's Science, Dr. Urfer held positions with increasing responsibilities at Genentech Inc., Novartis Pharma AG and AGY Therapeutics. Most recently, Dr. Urfer served as Senior Vice President of Drug Discovery and Development at AGY.

"Dr. Urfer is an exceptional addition to our senior management team to advance our clinical development program and corporate business development. With his international scientific and business experience he represents a perfect fit and will play a key role in the achievement of our corporate goals" commented Mr. Akihiko Shimauchi, President and COO.

### **About M's Science Corporation**

M's Science is a privately held biopharmaceutical company dedicated to the discovery and development of treatments of central nervous system (CNS) disorders and cancer. M's Science is currently developing two clinical stage products.

SA4503 is a potent and selective agonist of the sigma-1 receptor. SA4503 enhances neuroregeneration by activation of plasticity pathways and facilitates the recovery of damaged CNS tissues from stress or ischemia-induced insults. In addition, SA4503 has neuromodulatory and cognitive enhancer activities. This product profile is unique and SA4503 thus provides a novel opportunity towards therapy of various CNS disorders. M's Science will initially focus its clinical development of SA4503 on the enhancement of recovery from stroke and on the treatment of major depressive disorder.

HF10 is a natural isolate of an attenuated herpes simplex virus and possesses strong tumor killing ability. HF10 is administered intratumorally thus limiting or eliminating adverse effects commonly observed with cytotoxic therapy. HF10's activity in patients with breast or head & neck cancer has been demonstrated in studies conducted in collaboration with the University of Nagoya. M's Science initially develops HF10 for the treatment of head & neck cancer and intends to expand its application to other cancers.



---

## Contact

M's Science Corporation

Address: 5-5-2, Minatojima-Minamimachi, Chuo-ku, Kobe 650-0047, Japan

Tel: +81-78-388-6000 Fax: +81-78-388-6001

E-mail: [info@m-sci.com](mailto:info@m-sci.com)

M's Science Corporation in the United States

[roman.urfer@ms-science.com](mailto:roman.urfer@ms-science.com)